查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010052

成瘾药物市场：2026-2032年全球市场预测（按产品类型、剂型、给药途径、药物类别、分销管道和最终用户划分）

Addiction Disorders Drugs Market by Product Type, Dosage Form, Administration Route, Drug Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，成瘾药物市场价值将达到 288.9 亿美元，到 2026 年将成长到 306.7 亿美元，到 2032 年将达到 453.4 亿美元，复合年增长率为 6.65%。

主要市场统计数据
基准年 2025 288.9亿美元
预计年份：2026年 306.7亿美元
预测年份 2032 453.4亿美元
复合年增长率 (%) 6.65%

简要概述当前影响成瘾治疗和策略决策的临床、监管和商业性趋势。

成瘾是一个持续且不断演变的公共卫生挑战，涉及临床实践、法律规范和商业策略的交汇点。本执行摘要整合了治疗方法、给药技术和护理服务模式的最新进展，旨在帮助相关人员确定投资重点并应对营运风险。本文重点关注药物创新、与学名药的竞争以及不断演变的患者就医途径之间的相互作用，从实用观点出发，为临床、监管和商业部门的决策提供支持。

概述了正在重塑成瘾治疗中治疗方法的采用和竞争动态的关键技术、监管和护理模式变革。

成瘾药物治疗领域正经历着一场变革，其驱动力包括患者期望的提高、药物传输技术的进步以及医疗服务管道的变革。新的製剂技术使得药物作用时间更长、依从性更高成为可能，迫使保险公司和医疗服务提供者重新评估治疗流程。同时，数位疗法和远端医疗的融合，正以行为科学为基础，为药物治疗提供补充，并将治疗范围扩展到传统诊所之外。

本研究分析了累积关税措施如何重塑整个成瘾治疗供应链的韧性、筹资策略和製造在地化。

关税措施的累积影响为成瘾治疗领域的采购、生产选择和定价策略带来了新的复杂性。关税相关的成本压力促使企业重新评估其供应商网络，尽可能优先考虑在地采购，重新谈判长期供应合约以稳定投入成本，并降低对政策突变的脆弱性。这些调整对依赖全球活性成分采购的学名药生产商以及维持复杂多层供应链的品牌药开发商都具有重大意义。

为了实现策略清晰，我们进行了多层次的細項分析，将产品形式、给药途径和治疗领域与分销管道和最终用户的实际情况联繫起来。

一套精细的市场区隔架构清楚展现了临床需求、生产复杂性和商业性差异化之间的交集。我们首先检视产品类型，调查品牌药和学名药的供应情况，每种产品在定价、监管环境和商业化方面都有其独特的考量。在剂型方面，我们研究了胶囊、薄膜、注射、贴片和片剂等各种剂型的市场情况，每种剂型都面临不同的配方挑战、患者遵从性和分销要求。最后，我们考虑给药途径，包括注射、口服、舌下和经皮，每种途径都会影响起效速度、监测需求以及对不同患者群体的适用性。

区域间在监管多样性、医疗保健服务模式和製造业实力方面的观点，造成了医疗服务取得和普及趋势的差异。

区域趋势影响着医疗服务的可近性、监管路径和商业性模式。首先，在美洲，医疗保健体系涵盖了以公共保险主导的模式以及公私混合模式。政策辩论和报销机制对该地区处方药的上市和推广时间表有显着影响。临床医生网络、专科治疗中心和减害措施是影响治疗推广和持续性的关键相关人员。此外，美洲在整合式医疗模式方面不断创新，将药物治疗与行为疗法和数位化支持相结合，从而改变了治疗方法的处方和监测方式。

深入了解创新者、非专利生产商、契约製造生产商、经销商和数位健康合作伙伴在塑造竞争定位和合作中的作用。

成瘾治疗领域的竞争动态是由许多创新公司、专业製药公司、非专利生产商、合约研发生产机构 (CDMO) 以及分销合作伙伴共同塑造的。创新公司专注于透过新型配方、缓释平台和拓展适应症来提升治疗效用，从而实现差异化；而非专利生产商则优先考虑成本竞争力、供应可靠性和监管灵活性，以获得进入大众市场管道的机会。契约製造生产商和 CDMO 在扩大产能、快速扩大新剂型规模以及分散品牌药和非专利组合的风险方面发挥着至关重要的作用。

透过加强供应韧性、创新给药形式和整合照护模式，采取实际有效的策略步骤，加速推广应用并改善治疗效果。

该领域的领导者应采取一系列切实有效且影响深远的措施，以增强韧性、加速部署并改善患者治疗效果。首先，应优先投资于製剂和给药途径的创新，以解决用药依从性和监测方面的挑战，并使产品开发与患者的实际需求和支付方的证据要求保持一致。其次，应透过双重采购、区域製造能力和透明的供应商关係来增强供应链韧性，同时控製成本并降低地缘政治和关税相关风险。

采用高度透明的混合方法研究方法，结合严谨的二手资料分析、针对性的一手访谈和情境评估，以获得可靠的见解。

本研究途径结合了对二手证据的系统性回顾和有针对性的一手调查，以期获得广度和深度兼具的洞见。二手分析包括同行评审文献、临床指南综述、监管文件以及现有的匿名处方和使用资料集。这些资讯来源为分析提供了潜在的临床和监管背景、历史治疗模式以及已发表的安全性和有效性数据。在二手分析阶段，我们优先考虑透明度、可重复性和资讯来源的仔细检验，以避免过度依赖单一资讯来源。

在不断变化的成瘾治疗领域中，将临床创新、供应弹性和对综合护理的投资转化为策略优势的关键点。

总而言之，目前成瘾药物治疗的现况呈现出多种因素交互作用的复杂局面，既存在风险也蕴藏机会。给药方法和製剂的创新，以及不断扩展的综合护理模式，正促使人们重新审视药物的采纳，不再仅仅关注传统的疗效指标，而是更加关注患者体验、用药依从性和系统整合。同时，地缘政治和政策趋势也促使人们重新评估供应链设计和筹资策略，进一步凸显了韧性和弹性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：成瘾治疗市场：依产品类型划分

  • 品牌商品
  • 非专利的

第九章：以剂型分類的成瘾治疗市场

  • 胶囊
  • 电影
  • 注射液
  • 修补
  • 药片

第十章：按给药途径分類的成瘾治疗市场

  • 注射药物
  • 口服
  • 舌下
  • 经皮

第十一章：成瘾治疗市场：依药物类别划分

  • 酒精
    • Acamprosate
    • Disulfiram
    • 纳曲酮
  • 尼古丁
    • Varenicline
  • 阿片类药物
    • Buprenornhine
    • 梅塔顿
    • 纳曲酮

第十二章：成瘾治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：成瘾治疗市场：依最终使用者划分

  • 诊所
  • 居家照护设施
  • 医院

第十四章：成瘾治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：成瘾治疗市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：成瘾治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国成瘾治疗市场

第十八章：中国成瘾治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Limited
  • Alkermes plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc
  • BioDelivery Sciences International Inc
  • Camurus AB
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Insys Therapeutics Inc
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals PLC
  • Orexo AB
  • Pfizer Inc
  • Purdue Pharma LP
  • Reckitt Benckiser Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Titan Pharmaceuticals Inc
  • Viatris Inc
Product Code: MRR-434CCDA05183

The Addiction Disorders Drugs Market was valued at USD 28.89 billion in 2025 and is projected to grow to USD 30.67 billion in 2026, with a CAGR of 6.65%, reaching USD 45.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.89 billion
Estimated Year [2026] USD 30.67 billion
Forecast Year [2032] USD 45.34 billion
CAGR (%) 6.65%

A concise orientation to the current clinical, regulatory, and commercial dynamics shaping addiction disorder therapies and strategic decision making

Addiction disorders present a persistent and evolving public health challenge that intersects clinical practice, regulatory oversight, and commercial strategy. This executive summary synthesizes the latest developments across therapeutic modalities, delivery technologies, and care delivery models to help stakeholders prioritize investments and respond to operational risks. It emphasizes the interplay between pharmacologic innovation, generic competition, and shifting patient access pathways while framing the discussion in a pragmatic way that supports decision making across clinical, regulatory, and commercial functions.

Patients, payers, providers, and manufacturers are adapting to a landscape where treatment expectations are changing and where integrated care models increasingly determine outcomes. As a result, therapeutic selection is not only influenced by efficacy and safety but also by formulation, route of administration, and distribution flexibility that together shape adherence and continuity of care. The introduction of novel formulations and the repositioning of established therapies for extended indications have intensified competition and created new opportunities for differentiation through patient-centric delivery systems.

This summary highlights transformative shifts and regulatory pressures, examines how tariff dynamics are reshaping procurement and supply chain strategies, and articulates segmentation and regional perspectives critical for strategic planning. The intent is to equip decision-makers with a clear, evidence-based narrative that supports targeted investment and operational adjustments in the near term and over a multi-year horizon.

An overview of the major technological, regulatory, and care model shifts reshaping therapeutic adoption and competitive dynamics in addiction treatment

The landscape for addiction disorder therapeutics is undergoing transformative shifts driven by patient expectations, technological advances in drug delivery, and changes in care delivery pathways. New formulation technologies are enabling longer-acting and more adherent-compatible options, which in turn are prompting payers and providers to reassess treatment algorithms. Concurrently, digital therapeutics and telehealth integration are supplementing pharmacologic approaches with behaviorally informed support, expanding the scope of treatment beyond traditional clinic walls.

Consolidation across specialty pharmacies, distributors, and contract manufacturers is altering bargaining power and creating opportunities for vertically integrated models that enhance supply resilience and reduce time to patient. Regulatory flexibility around expanded labeling and risk evaluation plans is enabling faster uptake of repurposed agents, while ongoing vigilance on safety profiles continues to shape prescribing behavior. Moreover, the maturation of real-world evidence generation is providing payers and clinicians with richer data on comparative effectiveness, adherence patterns, and long-term outcomes, thereby influencing coverage and formulary decisions.

Taken together, these shifts underscore a move toward holistic care models that combine pharmaceutical innovation with delivery systems and digital supports. For stakeholders, the priority is to align product development, commercial strategy, and evidence generation to these broader care trends so that therapies are optimized for both clinical impact and real-world adoption.

Analyzing how cumulative tariff measures have reshaped supply chain resilience, procurement strategies, and manufacturing localization across addiction therapy supply chains

The cumulative effect of tariff actions has introduced a new layer of complexity to procurement, manufacturing choices, and pricing strategies for addiction disorder therapies. Tariff-related cost pressures have incentivized firms to reassess supplier networks, prioritize local sourcing where feasible, and renegotiate long-term supply agreements to stabilize input costs and reduce vulnerability to sudden policy shifts. These adjustments have implications for generic manufacturers that rely on global active pharmaceutical ingredient sourcing and for branded developers that maintain complex, multi-tiered supply chains.

In response to tariff pressures, pharmaceutical firms are accelerating strategic initiatives such as nearshoring of critical manufacturing steps, investment in dual sourcing, and increased inventory buffers to preserve continuity of supply. These mitigation tactics, while practical, can increase operational complexity and working capital requirements. At the same time, health systems and payers are reviewing procurement frameworks to favor suppliers with demonstrated supply chain resilience, preferring predictable availability over marginal price advantages when disruptions could compromise patient care.

Regulatory agencies and trade policymakers are also part of the equation, as changes in import duties can prompt adaptive policy interventions and bilateral negotiations that alter the competitive environment. Ultimately, the combined effect of tariffs and corresponding industry responses is a heightened emphasis on supply chain transparency, risk management, and collaboration between manufacturers, distributors, and health systems to ensure uninterrupted access to essential addiction disorder therapies.

A layered segmentation analysis linking product formats, administration routes, and therapeutic classes to distribution channels and end-user realities for strategic clarity

A nuanced segmentation framework clarifies where clinical demand, manufacturing complexity, and commercial differentiation converge, starting with product type where the landscape is examined across branded and generic offerings, each bringing distinct pricing, regulatory, and commercialization considerations. Moving to dosage form, the market is studied across capsule, film, injectable solution, patch, and tablet formats, which carry different formulation challenges, patient adherence profiles, and distribution requirements. Administration route is considered across injectable, oral, sublingual, and transdermal pathways, with each route influencing onset of action, monitoring needs, and suitability for diverse patient populations.

Drug class segmentation is particularly instructive for clinical and portfolio strategy. The alcohol disorder category is examined across acamprosate, disulfiram, and naltrexone, with each of these agents further analyzed in terms of branded and generic availability and their implications for treatment positioning. Nicotine dependence therapies are assessed across bupropion, nicotine replacement therapy, and varenicline; bupropion and varenicline are evaluated for branded and generic dynamics while nicotine replacement therapy is explored across gum, inhaler, lozenge, and patch forms that differ in pharmacokinetics and patient preference. The opioid disorder category includes buprenorphine, methadone, and naltrexone, with attention to branded and generic variations that affect access, prescriber behavior, and dispensing controls.

Distribution channel segmentation examines hospital pharmacy, online pharmacy, and retail pharmacy pathways, recognizing that each channel has different regulatory compliance, reimbursement mechanisms, and opportunities for patient engagement. Finally, end user segmentation covers clinics, homecare settings, and hospitals, highlighting how the locus of care influences adherence support, monitoring intensity, and adoption of novel delivery systems. Together, this layered segmentation provides a granular lens through which product development, commercialization, and health system strategies can be aligned to clinical and operational realities.

Regional perspectives on regulatory diversity, care delivery models, and manufacturing strengths that drive differentiated access and adoption dynamics

Regional dynamics shape access, regulatory pathways, and commercial approaches, beginning with the Americas where health systems vary from public payer-driven models to mixed public-private arrangements. In this region, policy debates and reimbursement frameworks strongly influence formulary placement and adoption timelines. Clinician networks, specialty treatment centers, and harm-reduction initiatives are critical stakeholders that affect uptake and continuity of care. Additionally, the Americas continue to witness innovation in integrated care models that combine pharmacotherapy with behavioral and digital supports, which alters how therapies are prescribed and monitored.

The Europe, Middle East & Africa region presents a diverse regulatory mosaic with differing approval timelines, pricing controls, and reimbursement mechanisms. In many jurisdictions, centralized procurement and stringent cost-effectiveness evaluations determine access, while subregional variations in care infrastructure influence distribution channel strategy. The region also sees growing emphasis on community-based programs and public health interventions that prioritize broad access to evidence-based therapies, which shapes demand for formulations that support adherence and simplified delivery.

Asia-Pacific is characterized by rapid adoption of novel delivery technologies, expanding private healthcare sectors, and strong manufacturing capabilities that position the region as both a consumer and producer of addiction disorder therapeutics. Regulatory harmonization efforts and investments in local manufacturing are creating opportunities for faster market entry, while telehealth expansion is enabling distributed models of care that reach underserved populations. Across regions, stakeholders must tailor commercialization, evidence generation, and supply chain strategies to local payer dynamics and care delivery configurations.

Insights into the roles of innovators, generics, contract manufacturers, distributors, and digital health partners shaping competitive positioning and collaboration

Competitive dynamics in the addiction therapies arena are shaped by a mix of originator companies, specialty manufacturers, generic producers, contract development and manufacturing organizations, and distribution partners. Innovator firms are focused on differentiation through novel formulations, extended-release platforms, and indications that expand therapeutic utility, while generic manufacturers emphasize cost competitiveness, supply reliability, and regulatory agility to capture volume-driven channels. Contract manufacturers and CDMOs play a pivotal role in enabling capacity expansion, rapid scale-up of new dosage forms, and risk diversification for both branded and generic portfolios.

Distribution and specialty pharmacy players are increasingly influential in shaping patient access, particularly for therapies requiring close monitoring or restricted dispensing. These intermediaries are integrating services such as adherence support, prior-authorization management, and home delivery, which affect patient continuity and payer perceptions. Meanwhile, digital health companies and telemedicine providers are emerging as complementary stakeholders that drive engagement and long-term management, especially when pharmacotherapy is combined with behavioral interventions.

Across these categories, alliances and strategic partnerships are common as organizations seek to combine clinical expertise, supply chain resilience, and channel reach. The most successful companies are those that integrate evidence generation with market access planning, invest in patient support infrastructure, and demonstrate operational agility to respond to regulatory and policy shifts. For decision-makers, understanding these competitive roles is essential to identifying potential collaborators, acquisition targets, and differentiation opportunities within portfolios.

Practical high-impact strategic steps for strengthening supply resilience, innovating delivery formats, and integrating care models to drive adoption and outcomes

Leaders in the field should pursue a set of pragmatic, high-impact actions to strengthen resilience, accelerate adoption, and improve patient outcomes. First, prioritize investments in formulation and route of administration innovations that address adherence and monitoring challenges, aligning product development with real-world patient needs and payer evidence requirements. Second, strengthen supply chain resilience through dual sourcing, regional manufacturing capacity, and transparent supplier relationships to mitigate geopolitical and tariff-related risks while maintaining cost discipline.

Third, build integrated value propositions that combine pharmacologic therapy with behavioral, digital, and telehealth supports to enhance outcomes and create payer-relevant differentiation. Fourth, engage early and proactively with payers and regulatory bodies to ensure that clinical development and evidence generation plans meet real-world decision criteria, smoothing pathways to coverage and uptake. Fifth, establish distribution strategies that reflect channel-specific dynamics, including partnerships with specialty and online pharmacies where adherence support and patient management services can be delivered effectively.

Finally, adopt an outcomes-focused commercial model that measures real-world effectiveness, patient retention, and health economic impact to guide portfolio prioritization and pricing discussions. By implementing these actions, organizations can better navigate policy uncertainty, enhance patient access, and create durable competitive advantages in the evolving treatment landscape.

A transparent mixed-methods research pathway combining rigorous secondary analysis with targeted primary interviews and scenario assessment for robust insights

The research approach combined systematic secondary evidence review with targeted primary engagement to ensure both breadth and depth of insight. Secondary analysis included peer-reviewed literature, clinical guideline reviews, regulatory documentation, and anonymized prescription and utilization datasets where accessible. These sources established the clinical and regulatory context, historical treatment patterns, and published safety and efficacy profiles that anchor the analysis. The secondary phase prioritized transparency, reproducibility, and careful source triangulation to avoid undue reliance on any single information stream.

Primary research complemented secondary findings through structured interviews with clinicians, specialty pharmacists, payer representatives, and manufacturing and distribution executives. These engagements provided contemporary perspectives on adoption barriers, supply chain practices, and formulary decision drivers. Interview protocols were designed to elicit practical insights on adherence challenges, real-world outcomes, and operational considerations for different dosage forms and administration routes. Responses were anonymized and synthesized to identify convergent themes and dissenting viewpoints.

Analytical methods included qualitative synthesis, comparative assessment of formulation and delivery trade-offs, and scenario analysis focused on supply chain and policy contingencies. Throughout, the methodology emphasized balanced interpretation, rigorous cross-validation of evidence, and clear documentation of assumptions and limitations so that users can assess applicability to their specific strategic questions.

Key takeaways that tie clinical innovation, supply resilience, and integrated care investments to strategic advantage in the evolving addiction treatment environment

In summary, the addiction disorder therapeutics landscape is characterized by converging forces that create both risk and opportunity. Innovations in delivery and formulation, combined with expanding models of integrated care, are shifting the determinants of adoption beyond classical efficacy metrics to include patient experience, adherence, and system integration. At the same time, geopolitical and policy developments are prompting a reappraisal of supply chain design and procurement strategies, reinforcing the importance of resilience and agility.

Strategically, organizations that align product development with payer and provider evidence needs, invest in differentiated delivery mechanisms, and build partnerships across distribution and digital health channels will be best positioned to capture clinical and commercial value. Operationally, strengthening supplier relationships, diversifying manufacturing footprints, and enhancing transparency will mitigate exposure to tariff and policy volatility. Finally, prioritizing real-world evidence generation and outcomes measurement will support coverage decisions and demonstrate value to stakeholders across the continuum of care.

Taken together, these conclusions suggest a pathway for action that balances near-term operational safeguards with medium-term investments in innovation and integrated care capabilities, thereby improving the prospects for sustainable impact in patient outcomes and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Addiction Disorders Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Addiction Disorders Drugs Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Film
  • 9.3. Injectable Solution
  • 9.4. Patch
  • 9.5. Tablet

10. Addiction Disorders Drugs Market, by Administration Route

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Sublingual
  • 10.4. Transdermal

11. Addiction Disorders Drugs Market, by Drug Class

  • 11.1. Alcohol
    • 11.1.1. Acamprosate
    • 11.1.2. Disulfiram
    • 11.1.3. Naltrexone
  • 11.2. Nicotine
    • 11.2.1. Varenicline
  • 11.3. Opioid
    • 11.3.1. Buprenorphine
    • 11.3.2. Methadone
    • 11.3.3. Naltrexone

12. Addiction Disorders Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Addiction Disorders Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare Settings
  • 13.3. Hospitals

14. Addiction Disorders Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Addiction Disorders Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Addiction Disorders Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Addiction Disorders Drugs Market

18. China Addiction Disorders Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accord Healthcare Limited
  • 19.6. Alkermes plc
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bausch Health Companies Inc
  • 19.9. BioDelivery Sciences International Inc
  • 19.10. Camurus AB
  • 19.11. Cipla Limited
  • 19.12. GlaxoSmithKline PLC
  • 19.13. Hikma Pharmaceuticals PLC
  • 19.14. Indivior PLC
  • 19.15. Insys Therapeutics Inc
  • 19.16. Johnson & Johnson
  • 19.17. Mallinckrodt Pharmaceuticals PLC
  • 19.18. Orexo AB
  • 19.19. Pfizer Inc
  • 19.20. Purdue Pharma L.P.
  • 19.21. Reckitt Benckiser Pharmaceuticals Inc
  • 19.22. Teva Pharmaceutical Industries Ltd
  • 19.23. Titan Pharmaceuticals Inc
  • 19.24. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)